Jill Corre

List of Publications by Year
in descending order

80	4,647	159358 30	114278 63
papers	citations	h-index	g-index

82	82	82	6449
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. Blood Advances, 2022, 6, 672-678.	2.5	8
2	Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63, 1008-1013.	2.8	4
3	Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood, 2022, 139, 2666-2672.	0.6	12
4	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood, 2022, 139, 1160-1176.	0.6	11
5	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 2022, 139, 2747-2757.	0.6	16
6	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284.	2.6	24
7	Risk factors in multiple myeloma: is it time for a revision?. Blood, 2021, 137, 16-19.	0.6	37
8	del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood, 2021, 137, 1192-1195.	0.6	48
9	Undetectable MRD can change the deal. Blood, 2021, 137, 5-6.	0.6	3
10	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
11	Multiple myeloma with hungry plasma cells. British Journal of Haematology, 2021, 193, 443-443.	1.2	0
12	Multiple Myeloma: Heterogeneous in Every Way. Cancers, 2021, 13, 1285.	1.7	15
13	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood, 2021, 138, 113-121.	0.6	22
14	Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCRâ€ABL1 detection failure using RTâ€MLPA (positive RTâ€qPCR). EJHaem, 2021, 2, 655-656.	0.4	0
15	Improved survival in multiple myeloma during the 2005â€“2009 and 2010â€“2014 periods. Leukemia, 2021, 35, 3600-3603.	3.3	11
16	Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients. Quantitative Imaging in Medicine and Surgery, 2021, 11, 4299-4309.	1.1	2
17	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1378-1390.	5.1	84
18	Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow. Clinical Chemistry, 2021, 67, 1689-1698.	1.5	24

#	Article	IF	Citations
19	Doubleâ€hit multiple myeloma with atypical â€œfaggotâ€•cells. British Journal of Haematology, 2021, , .	1.2	0
20	Why is amyloidosis not multiple myeloma?. Blood, 2021, 138, 1514-1515.	0.6	0
21	IgM-MM is predominantly a preâ€“germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood, 2021, 138, 1980-1985.	0.6	11
22	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. Journal of Clinical Oncology, 2020, 38, 3107-3118.	0.8	45
23	Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers, 2020, 12, 3497.	1.7	10
24	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica, 2020, 105, e480-483.	1.7	42
25	Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 3854.	1.8	7
26	Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells. Stem Cells International, 2020, 2020, 1-9.	1.2	5
27	Human Bone Marrow Is Comprised of Adipocytes with Specific Lipid Metabolism. Cell Reports, 2020, 30, 949-958.e6.	2.9	67
28	Crowded bone marrow plasma cells. Blood, 2020, 135, 79-79.	0.6	0
29	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood, 2019, 133, 1217-1221.	0.6	79
30	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	6.3	665
31	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1657-1665.	0.8	111
32	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia, 2019, 33, 2324-2330.	3.3	33
33	CytogÃ©nÃ©tique et gÃ©nÃ©tique molÃ©culaire du myÃ©lome multiple. Revue Francophone Des Laboratoires, 2019, 2019, 50-57.	0.0	1
34	Risk-Based Therapeutic Strategies. Cancer Journal (Sudbury, Mass), 2019, 25, 54-58.	1.0	4
35	Multiple myeloma immunophenotyping: method validation. Hematologie, 2019, 25, 248-272.	0.0	0
36	Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e3-e4.	0.2	18

#	Article	IF	Citations
37	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia, 2019, 33, 313-318.	3.3	17
38	Prognosis of Myeloma/Genetics of Myeloma. , 2018, , 645-649.		0
39	IgG lymphoplasmacytic lymphoma: a case report. Annales De Biologie Clinique, 2018, 76, 665-668.	0.2	1
40	Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 675-680.	1.8	23
41	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood, 2018, 132, 2778-2780.	0.6	18
42	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances, 2018, 2, 2811-2813.	2.5	69
43	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	0.6	301
44	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	1.7	86
45	Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia, 2018, 32, 2636-2647.	3.3	94
46	Genomics of Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 963-967.	0.8	85
47	Light chain multiple myeloma: when the response will it be evaluated by serum free light chains?. Hematologie, 2016, 22, 393-394.	0.0	0
48	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood, 2016, 128, 2941-2948.	0.6	58
49	Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach. , 2016, , .		0
50	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. Blood, 2015, 126, 2713-2719.	0.6	92
51	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood, 2015, 125, 2095-2100.	0.6	82
52	Genetics of multiple myeloma: another heterogeneity level?. Blood, 2015, 125, 1870-1876.	0.6	107
53	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood, 2015, 126, 191-191.	0.6	50
54	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget, 2015, 6, 8388-8396.	0.8	69

#	Article	IF	Citations
55	Growth Differentiation Factor 15 in Multiple Myeloma: A Microenvironment Factor Predictive of Response to Treatment?. Acta Haematologica, 2014, 131, 170-172.	0.7	1
56	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2014, 32, 2712-2717.	0.8	243
57	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica, 2014, 99, 1236-1238.	1.7	35
58	Blastic island in acute myeloid leukemia. Blood, 2014, 123, 1986-1986.	0.6	0
59	Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. Haematologica, 2014, 99, 474-480.	1.7	61
60	Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial. Blood, 2014, 124, 180-180.	0.6	3
61	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. Blood, 2014, 124, 2036-2036.	0.6	1
62	in Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study. Blood, 2014, 124, 641-641.	0.6	3
63	Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy. Blood, 2014, 124, 3396-3396.	0.6	0
64	Prognostic Implication of Genetic Changes (Cytogenetics, and FISH, Gains and Losses of DNA by SNP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		0
65	Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?. Stem Cells Translational Medicine, 2013, 2, 946-952.	1.6	161
66	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. Clinical Cancer Research, 2013, 19, 4634-4637.	3.2	12
67	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood, 2013, 121, 822-829.	0.6	189
68	Myeloma: a subclonal disease?. Hematologie, 2013, 19, 383-387.	0.0	0
69	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research, 2012, 72, 1395-1406.	0.4	90
70	Dualâ€energy Xâ€ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma. European Journal of Haematology, 2012, 88, 388-395.	1.1	12
71	Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study. Blood, 2012, 120, 196-196.	0.6	2
72	1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients. Blood, 2012, 120, 933-933.	0.6	13

#	Article	IF	Citations
73	The Impact of Genomics on the Management of Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1200-1206.	2.3	9
74	CR As Major End-Point After Consolidation for Multiple Myeloma Patients Eligible to High Dose Therapy. Blood, 2011, 118, 1858-1858.	0.6	0
75	Comparison of Stromal Cells of Adipose Tissue From Multiple Myeloma Patients and Healthy Donors. Blood, 2010, 116, 2979-2979.	0.6	0
76	Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome. Blood, 2008, 112, 2700-2700.	0.6	0
77	CD200 is a new prognostic factor in multiple myeloma. Blood, 2006, 108, 4194-4197.	0.6	205
78	Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. Journal of Cellular Physiology, 2006, 208, 282-288.	2.0	120
79	Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. British Journal of Haematology, 2005, 129, 118-129.	1.2	861
80	Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34+ cells. British Journal of Haematology, 2004, 127, 344-347.	1.2	54